Roivant Sciences
$7Bpaper valuation
// OVERVIEW
Roivant Sciences is a pharmaceutical holding company that buys distressed or deprioritized drug candidates from major pharma companies, spins them into subsidiary biotech companies (Immunovant, Dermavant, Enzyvant), then attempts to push those candidates through clinical trials and regulatory approval. The model is arbitrage on Big Pharma's asset triage decisions — betting that a drug Pfizer or GSK deemed not worth pursuing can be repositioned, rebranded, or re-risked into a commercial product. The company has raised over $3 billion, launched more than 20 subsidiary biotechs, and delivered exactly one FDA-approved drug to market.
// HQ
New York, United States
// STATUS
PRIVATE
// FOUNDED
2014
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
biotechnology
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
Roivant does not develop novel therapeutic mechanisms — it acquires late-stage clinical assets that original developers abandoned or deprioritized, often in autoimmune, dermatology, or rare disease indications. The operational model relies on agile clinical trial execution, regulatory pathway optimization, and the thesis that large pharma companies systematically undervalue assets that do not fit their blockbuster portfolios. The only marketed product, Vtama for plaque psoriasis, came through subsidiary Dermavant and generates under $200 million in annual revenue against a development cost Roivant will not disclose.
// WOWLS ASSESSMENT
The core problem is that Big Pharma companies have become very sophisticated at asset triage — if Pfizer kills a Phase 2 program it is usually because the efficacy data does not justify the commercialization risk, not because Pfizer lacks the vision to see its potential. Roivant's largest subsidiary, Immunovant, is developing batoclimab for autoimmune conditions — the drug failed a Phase 2 trial for myasthenia gravis in 2021, Roivant restructured the subsidiary and continued development anyway, and the company is now betting $7 billion in parent valuation on indications that the original developer did not pursue. The business model requires being systematically smarter than the R&D committees at GSK, Pfizer, and Takeda about which terminated programs were actually overlooked gems — and the scorecard is 1 approved drug from 20+ subsidiaries and $3 billion deployed. Most of the subsidiary companies have been shut down, merged, or restructured after their lead assets failed to show sufficient efficacy.
// WHY WOWLS HUNTS THIS
The company is a $7 billion bet that pharmaceutical companies systematically misprice their own clinical assets — and a decade of execution has produced one commercial drug and a graveyard of shuttered subsidiaries. Immunovant, the largest remaining bet, is developing a drug that already failed a Phase 2 trial under its original developer.
// VALUATION NOTE
Peak private valuation reached $7B in 2021 based on subsidiary IPO valuations (Immunovant, Aruvant). Current parent company valuation is difficult to assess given most subsidiaries have been restructured or shut down. Immunovant market cap is $8B as of 2024, but Roivant owns approximately 60%, suggesting parent NAV below stated $7B peak.
VERDICT: PAPER TIGER — ROIVANT HAS SPENT $3 BILLION BUYING DRUG CANDIDATES THAT BIG PHARMA DISCARDED, LAUNCHED 20+ SUBSIDIARY COMPANIES, AND DELIVERED ONE FDA-APPROVED PRODUCT GENERATING UNDER $200M ANNUALLY — THE MODEL REQUIRES BEING SMARTER THAN EVERY R&D COMMITTEE AT EVERY MAJOR PHARMA COMPANY ABOUT WHICH TERMINATED PROGRAMS WERE ACTUALLY OVERLOOKED, AND THE EVIDENCE SUGGESTS THOSE COMMITTEES KNEW EXACTLY WHAT THEY WERE DOING
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Roivant Sciences.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Roivant Sciences?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN